Pembrolizumab 200 mg IV infusion

Phase 2

MERCK (MRK)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

MRKPhase 2$281.2B

Pembrolizumab 200 mg IV infusion Phase 2 Est. Readout

Pembrolizumab 200 mg IV infusion• Stage IIIB(N2) Non-small Cell Lung Cancer70

Q3 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in Stage IIIB(N2) Non-small Cell Lung Cancer

View Full Landscape

Drug Information

Target Indication

Stage IIIB(N2) Non-small Cell Lung Cancer

Clinical Trial

NCT05894889

Last updated: 8/25/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Pegylated interferon alfa-2b (SCH 54031)Phase 3

Hepatitis C, Chronic

ElbasvirPhase 3

Hepatitis C

V260Phase 3

Rotavirus Gastroenteritis

Vericiguat tabletPhase 3

Heart Failure

MK-8591APhase 3

HIV-1 Infection

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts